Skip to content
buyNotable cluster of 2

Broadwood Partners, L.p. bought $3.9M of IMDX

owner at Oncocyte Corp. 1,315,339 shares at an average of $2.95, traded Oct 2, 2024, filed Oct 4, 2024.

Conviction score
60
Value
$3.9M
1,315,339 shares
Holdings after
6,244,405
+27% from before
From 52-week low
+47%
low $2.08, close $3.05
From 52-week high
-28%
high $4.26, as of Oct 2, 2024

Score components

  • Role
    10% owner
    +12
  • Trade size
    $3.9M at market
    +25
  • Relative to holdings
    Holdings up 27%
    +6
  • Price context
    28% below the 52-week high
    +4
  • Cluster
    2 insiders buying within 14 days
    +8
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Median 6-month excess return +20% over 21 past buys
    +10
  • Outside holder
    A 10% owner who is not an officer or director
    -5

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +3.8%, 3m -18.0%, 6m -4.2%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

IMDXOct 12, 2026 · close 3.17
Since filing Oct 4, 2024: +9.7%SPY +38.9% · excess -29.2%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000919574-24-005764, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 2, 2024POpen-market purchase
Common Stock, no par value
+1,315,339$2.95$3.9M6,244,405Oct 4, 2024
Oct 2, 2024POpen-market purchase
Common Stock, no par valueindirect: Footnote
+0$0.00$06,244,405Oct 4, 2024

Related signals

Other insiders at Oncocyte Corp and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
45Moderate
IMDXbuy
Oncocyte Corp
Broadwood Partners, L.p.
owner
$2.0M
570,184 shares
+5%
40Moderate
IMDXbuy
Oncocyte Corp
Broadwood Partners, L.p.
owner
$653k
182,861 shares
+2%
32Weak
IMDXbuy
Oncocyte Corp
Broadwood Partners, L.p.
owner
$3.0M
521,739 shares
+5%
57Moderate
IMDXbuy 2
Oncocyte Corp
Andrea S. James
Chief Financial Officer
$200k
97,561 shares
+182%
50Moderate
IMDXbuy 2
Oncocyte Corp
Broadwood Partners, L.p.
owner
$11M
5,165,695 shares
+83%
30Weak
IMDXbuy 2
Oncocyte Corp
Patrick W Smith
owner
$192k
90,219 shares
+5%
31Weak
IMDXbuy 2
Oncocyte Corp
Andrew Arno
director
$26k
12,500 shares
+18%
38Weak
IMDXbuy
Oncocyte Corp
Andrea S. James
Chief Financial Officer
$46k
20,000 shares
+59%
52Moderate
IMDXbuy 2
Oncocyte Corp
Andrea S. James
Chief Financial Officer
$100k
33,670 shares
-
58Moderate
IMDXbuy 3
Oncocyte Corp
Andrew Arno
director
$100k
33,898 shares
+96%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Broadwood Partners, L.p. bought $3.9M of IMDX | InsiderTell